Catalyst Event
Pfizer Inc (PFE) · Other
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/23/2026, 12:00:00 AM
Pfizer and partner Valneva announced positive topline results from the Phase 3 trial of their Lyme disease vaccine candidate (PF-07307405), showing over 70% efficacy. The companies plan to seek regulatory approval.
Korean Translation
화이자와 파트너사 발네바, 라임병 백신 후보물질(PF-07307405)의 3상 임상시험에서 70% 이상의 효능을 보인 긍정적인 탑라인 결과를 발표함. 규제 당국에 승인을 신청할 계획임.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM